Clinical Trials Browser

INDUSTRY × Has results × PF-05280014 × Clear all

NCT01989676 2021-07-06

A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Phase 3 Completed

707 enrolled 20 charts

Breast Neoplasms

NCT02187744 2019-01-08

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Phase 3 Completed

226 enrolled 9 charts

Breast Neoplasms